Clinical Trial Update: Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating apatinib plus docetaxel as second-line treatment for advanced lung adenocarcinoma with wild-type EGFR; status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma

Drugs mentioned

• Apatinib (apatinib)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Lung Adenocarcinoma | Phase 1 | Status: UNKNOWN